TTNP (Titan Pharmaceuticals) Total Equity: $2.79 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TTNP Titan Pharmaceuticals Inc TTNP
9 GF Score
Price $4.61
View Full Analysis

What is Titan Pharmaceuticals Total Equity?

Titan Pharmaceuticals TTNP 9 Total Equity is $2.79 Mil as of Jun. 2025. GuruFocus rates TTNP with a GF Score™ of 9/100.

Titan Pharmaceuticals's total equity for the quarter that ended in Jun. 2025 was $2.79 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Titan Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Titan Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Titan Pharmaceuticals Total Equity Chart

Titan Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.53 5.14 1.36 6.64 2.44

Titan Pharmaceuticals Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.99 3.23 2.44 1.88 2.79
TTNP
9GF Score
Titan Pharmaceuticals Inc TTNP
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Titan Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Titan Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=2.923-0.483
=2.44

Titan Pharmaceuticals's Total Equity for the quarter that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=3.051-0.263
=2.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $2.79 Mil mean?
Titan Pharmaceuticals (TTNP) has a Total Equity of $2.79 Mil as of Jun. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Titan Pharmaceuticals and its competitors.
Is Titan Pharmaceuticals' Total Equity too high?
Titan Pharmaceuticals' current Total Equity is $2.79 Mil. Overall, Titan Pharmaceuticals has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Titan Pharmaceuticals' Total Equity compare to TCRT and SXTP?
Titan Pharmaceuticals' Total Equity of $2.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Titan Pharmaceuticals and its competitors. Titan Pharmaceuticals's current Total Equity is $2.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Titan Pharmaceuticals stock overvalued right now?
Titan Pharmaceuticals (TTNP) has a current Total Equity of $2.79 Mil. The current Total Equity is $2.79 Mil. Titan Pharmaceuticals' overall GF Score™ is 9/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Titan Pharmaceuticals (TTNP), the current Total Equity is $2.79 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Titan Pharmaceuticals Business Description

Address 400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
9GF Score

Get the complete analysis for TTNP

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.61
Price